ACTION II

ACTION II

A Clinical Trial In Overt Nephropathy II. A trial that asked whether pharmacologic inhibition of advanced glycated endproduct (AGE) production with pimagedine slowed the progression of chronic renal disease in type 2 diabetics.
Conclusion No. Safety concerns and lack of efficacy resulted in the drug’s sponsor ending the trial.